Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 3/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.31 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22487919 | 0.79 | GRM1 (0.35) | GRM1GRM5XDHCYP17A1NPSR1 | |
| SCHEMBL5432319 | 0.68 | GRM1 (0.42) | GRM1GRM5PDE2A | |
| SCHEMBL22487747 | 0.67 | XDH (0.42) | GRM1XDHHCAR1 | |
| SCHEMBL5437218 | 0.66 | MEN1 (0.46) | GRM1GRM5XDHHCAR1 | |
| SCHEMBL24422535 | 0.64 | GSK3B (0.36) | GSK3B | |
| SCHEMBL22488037 | 0.63 | HPGD (0.39) | GRM1XDHHCAR1 | |
| SCHEMBL22487730 | 0.63 | ACHE (0.37) | GSK3BXDHNPSR1 | |
| SCHEMBL3992299 | 0.62 | GSK3B (0.32) | GSK3B | |
| SCHEMBL11003505 | 0.60 | GSK3B (0.43) | GSK3B | |
| SCHEMBL10537854 | 0.59 | MAT2A (0.33) | GRM1CYP17A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | D. E. SHAW RESEARCH, LLC | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308165-A1 | Compounds as Ras Inhibitors and Use Thereof | KRAS, NRAS, HRAS | GSK3B 2312/4885KDM5B 4047/4885GRM1 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.